Skip to content


Anthim, Obiltoxaximab SFL (obiltoxaximab) is an antibody pharmaceutical. Obiltoxaximab was first approved as Anthim on 2016-03-18. It is used to treat anthrax, crohn disease, and graft vs host disease in the USA. It has been approved in Europe to treat anthrax.
Trade Name Obiltoxaximab SFL
Common Name Obiltoxaximab
Indication anthrax, crohn disease, graft vs host disease
Drug Class Monoclonal antibodies: toxin as a target
Get full access now